IT Type
Antibody-based IT
Description
The T cell receptor (TCR)/CD3 complex is the goal of a therapeutic strategy aimed at prolonging the survival time of allografts. The immunotoxin FN18-CRM9 consisting of the anti-CD3 monoclonal antibody FN18 and the mutated diphtheria toxin CRM9 can be used to prolong the survival time of allografts in preclinical transplant models.
Indication
Head and neck cancer, melanoma, and renal cell, ovarian, and colorectal carcinoma
Classification
Immuntoxin; biobetter
Construction
FN18-CRM9
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD3
Full Name
cluster of differentiation 3
Background
CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells).
Alternative Names
CD3
Antibody Clone
FN18
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Type
scFv
Antibody Indication
Head and neck cancer, melanoma, and renal cell, ovarian, and colorectal carcinoma
Toxic Moiety
CRM9
Organism
Corynebacterium
Family
Diphtheria toxin
Toxic MOA
CRM9 is a mutant form of diphtheria toxin (DT). Diphtheria toxin kills cells by inhibiting eukaryotic protein synthesis, and its mechanism of action has been extensively characterized. This potent toxin inactivates elongation factor (EF-2) required for protein synthesis. Specifically, diphtheria toxin transfers the ADP-ribose moiety of NAD to EF-2, and thus blocks the translational machinery of target cells.
The combination of the mutated diphtheria toxin CRM9 and FN18 can modulate the TCR/CD3 complex monoclonal antibody-mediated cross-linking, resulting in stronger protein tyrosine phosphorylation and CD3 internalization.
Head and neck cancer, melanoma, and renal cell, ovarian, and colorectal carcinoma
